Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
A meta-analysis of 14 studies (16 cohorts) incorporating 1751 participants was performed to evaluate the correlation between baseline neutrophil-to-lymphocyte ratio (NLR) and outcome of immune checkpoint inhibitors (ICI). The pooled hazard ratio (HR) suggested elevated pretreatment NLR was associated with poor OS (HR: 2.61, 95% confidence intervals (CI): 1.77–3.86, p < 0.00001) and PFS (HR: 1.74, 95% CI: 1.34–2.27, p < 0.0001). Stratified analyses on tumor types, ICI agents, the cutoff value of NLR and study regions exhibited the similar outcomes. This study demonstrated that elevated NLR was a predictor of poor OS and PFS for ICI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Capone, M., Giannarelli, D., Mallardo, D., Madonna, G., Festino, L., Grimaldi, A. M., Vanella, V., Simeone, E., Paone, M., Palmieri, G., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0383-1 · Cited by 497 · cited 1×
“(30) Italy NA 97 R melanoma nivolumab 5 OS/PFS Rosner et al.”
BackgroundSimeone, E., Gentilcore, G., Giannarelli, D., Grimaldi, A. M., Caracò, C., Curvietto, M., Esposito, A., Paone, M., Palla, M., Cavalcanti, E., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1545-8 · Cited by 253
Subudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611421113 · Cited by 226 · cited 1×
“Recently, a variety of novel biomarkers emerged to predict prognosis and guide clinical practice, involving programed cell death ligand 1 (PD-L1) (2), tumor mutation burden (TMB) (3), microsatellite instability (MSI) (4), mismatchrepair deficiency (dMMR) (5), the “inflamed phenotype” such as tumor infiltrating lymphoc…”
BackgroundNeutrophils: important contributors to tumor progression and metastasis
Swierczak, A., Mouchemore, K. A., Hamilton, J. A., & Anderson, R. L. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9594-9 · Cited by 220 · cited 10×
“Regarding tumor types, we found that high baseline NLR contributed to a poor OS in melanoma (HR: 2.51, 95% CI: 1.56–4.02, p¼ 0.0001, I2¼ 95%), in NSCLC (HR: 2.52, 95% CI: 1.40–4.55, p¼ 0.002, I2¼ 52”
BackgroundInfluential
Cited by
Neutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
Cupp, M. A., Cariolou, M., Tzoulaki, I., Aune, D., Evangelou, E., & Berlanga-Taylor, A. J. (2020) · BMC Medicine · doi:10.1186/s12916-020-01817-1 · Cited by 697
Valero, C., Lee, M., Hoen, D., Weiss, K., Kelly, D. W., Adusumilli, P. S., Paik, P. K., Plitas, G., Ladanyi, M., Postow, M. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20935-9 · Cited by 441
Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Journal of Immunology Research · doi:10.1155/2021/6661406 · Cited by 136
Zhang, N., Jiang, J., Tang, S., & Sun, G. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106677 · Cited by 109
Metadata
- Authors
- Xie, X., Liu, J., Yang, H., Chen, H., Zhou, S., Lin, H., Liao, Z., Ding, Y., Ling, L., & Wang, X.
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2019-07-03
- Volume
- 37
- Issue
- 6
- Pages
- 265-274
- ISSN
- 0735-7907 (ISSN-L)
- 1532-4192
- OpenAlex
- W2957912708
- Cited by
- 44
- References
- 7
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors. https://app.cochat.ai/papers/10.1080/07357907.2019.1639057
- The paper
- Xie, X., Liu, J., Yang, H., Chen, H., Zhou, S., Lin, H., Liao, Z., Ding, Y., Ling, L., & Wang, X. (2019). Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors. Cancer Investigation. https://doi.org/10.1080/07357907.2019.1639057
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.